Shanghai Fosun Pharmaceutical (600196) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached RMB 10.07 billion, up 6.93% year-over-year; net profit attributable to shareholders rose 13.87% to RMB 870.83 million.

• Four innovative drug applications were accepted and 14 clinical trial applications were approved by domestic and international regulators.

• Notable pipeline progress includes approvals and clinical advancements for drugs targeting oncology and rare diseases.

Financial highlights

• Operating income for Q1 2026 was RMB 1.36 billion, up 0.74% year-over-year.

• Net profit attributable to shareholders excluding non-recurring items increased 21.96% year-over-year to RMB 500.53 million.

• Basic and diluted EPS both rose 13.79% to RMB 0.33.

• Operating cash flow increased 8.8% year-over-year to RMB 1.15 billion.

• Total assets at quarter-end were RMB 122.97 billion, up 2.43% from year-end 2025.

Outlook and guidance

• Continued focus on innovation and internationalization, with new drug applications and clinical trials expected to drive future growth.